Zithromax — Revenues:
Pfizer Zithromax — Revenues: decreased by 0.9% to $112.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 29.1%, from $158.00M to $112.00M. Over 4 years (FY 2021 to FY 2025), Zithromax — Revenues: shows an upward trend with a 9.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates sustained market demand or successful lifecycle management for the product, while a decrease may signal increased generic competition or a shift in clinical prescribing patterns.
Detailed definition
This metric represents the total gross sales generated from the Zithromax product line, which is a key antibiotic therap...
Peer comparison
Comparable to revenue metrics for mature, off-patent, or legacy pharmaceutical brands at other large-cap drug manufacturers.
pfe_segment_zithromax_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $43.00M | $66.00M | $80.00M | $125.00M | $54.00M | $71.00M | $81.00M | $150.00M | $44.00M | $60.00M | $152.00M | $200.00M | $74.00M | $83.00M | $123.00M | $158.00M | $56.00M | $73.00M | $113.00M | $112.00M |
| QoQ Change | — | +53.5% | +21.2% | +56.3% | -56.8% | +31.5% | +14.1% | +85.2% | -70.7% | +36.4% | +153.3% | +31.6% | -63.0% | +12.2% | +48.2% | +28.5% | -64.6% | +30.4% | +54.8% | -0.9% |
| YoY Change | — | — | — | — | +25.6% | +7.6% | +1.3% | +20.0% | -18.5% | -15.5% | +87.7% | +33.3% | +68.2% | +38.3% | -19.1% | -21.0% | -24.3% | -12.0% | -8.1% | -29.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's zithromax — revenues:?
- Pfizer (PFE) reported zithromax — revenues: of $112.00M in Q1 2026.
- How has Pfizer's zithromax — revenues: changed year-over-year?
- Pfizer's zithromax — revenues: decreased by 29.1% year-over-year, from $158.00M to $112.00M.
- What is the long-term trend for Pfizer's zithromax — revenues:?
- Over 4 years (2021 to 2025), Pfizer's zithromax — revenues: has grown at a 9.5% compound annual growth rate (CAGR), from $278.00M to $400.00M.
- What does zithromax — revenues: mean?
- The total revenue generated from sales of the Zithromax antibiotic product line.